Figure 3.

Effects of 7-day application of pravastatin and cerivastatin on myotube diameter and contractile function. A, Representative images of myobundle cross-sections stained for β-spectrin. B, Quantification of myotube diameter from β-spectrin stainings normalized to drug-free control (n = 200 myotubes from 8 myobundles per group from N = 2 donors). C, Representative force traces during twitch and tetanic contraction. D, Quantification of specific force during tetanic contraction normalized to drug-free control (n = 8 myobundles, n = 1 technical replicate, from N = 2 donors). *p < .01 from CTL and ^#p < .001 from C10. CTL, drug-free control; P50, 250 nM pravastatin; P250, 250 nM pravastatin; C10, 10 nM cerivastatin; C100, 100 nM cerivastatin.